Crescent Biopharma develops innovative cancer therapies to treat solid tumors. Self-described as pioneering in this field.

Crescent Biopharma

Crescent Biopharma | 451 followers on LinkedIn. Illuminating a brighter future for treating solid tumors with potentially best-in-class therapies.

Interim CEO

Jonathan Violin

Chief Business Officer

Chris Doughty

📢 NEWS: GlycoMimetics has announced an agreement to acquire Crescent Biopharma and advance Crescent’s portfolio of novel biologics precision engineered to improve outcomes for patients with solid tumors — delivering superior efficacy to the current gold standard. Upon completion of the merger, the unified company will operate as Crescent, progressing lead assets CR-001, a cooperative PD-1 x VEGF bispecific antibody and CR-002, an antibody-drug conjugate for an undisclosed target with a topoisomerase inhibitor payload that may offer best-in-class efficacy. With a concurrent private financing of approximately $200 million led by Fairmount Funds Management LLC , Venrock , BVF PARTNERS, L.P , and a large investment management firm, Crescent expects to fund operations through 2027. Read the release here: https://lnkd.in/eHRSNgjp Learn more at www.crescentbiopharma.com . #SolidTumors #Oncology #CancerCare #Merger #Biotech

CRES

COM:CRESCENTBIOPHARMA

Crescent Biopharma